Nootropics and supplements
This category combines unrelated structures and evidence levels. The useful research approach is to separate identity, proposed target, measured assay, human evidence and formulation claims instead of treating “nootropic” as a mechanism.
Section 1Evidence ladderA registry record, receptor result and controlled human outcome are three different kinds of evidence.
Racetams and cholinergic compounds
Piracetam-related and choline-system materials
Mechanistic claims vary across compounds and often rely on older or narrow studies. Record the exact compound, endpoint and population before drawing comparisons.
Analytical noteVerify identity and salt form, then keep physical-property data separate from pharmacological claims.
Novel supplements
Single-ingredient research listings
For newer materials, absence of an indexed assay or clinical study should be shown plainly rather than filled with an inferred benefit.
Analytical noteUse qualified statements such as “no curated assay located” and retain the search date.
References
Historical books are included for provenance. Linked journal records and data services support the modern research and analytical sections.
- PubChem PUG REST documentationNational Center for Biotechnology Information.
- ChEMBL web-services documentationEuropean Bioinformatics Institute.